FIELD: pharmaceuticals; medicine.
SUBSTANCE: object 1 is a stable liquid composition for the introduction of an immunoconjugate containing an antibody to CD79b, containing an immunoconjugate, a buffering agent, sugar and a surfactant. Objects 2–4 are a stable lyophilized composition for the introduction of an immunoconjugate containing an antibody to CD79b, containing an immunoconjugate, polysorbate 20, succinic acid, sodium hydroxide and sucrose. Objects 4–7 are a stable liquid composition for administration, in particular intravenous, immunoconjugate containing an antibody to CD79b. Objects 8–10 are the use of the stable composition in the manufacture of a medicinal product for the treatment of a B-cell proliferative disorder in a patient.
EFFECT: stability of immunoconjugates containing an antibody to CD79b.
37 cl, 18 dwg, 7 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-CD79B ANTIBODIES, IMMUNOCONJUGATES AND METHODS FOR THEIR USE | 2019 |
|
RU2791984C2 |
| ANTI-CD79b ANTIBODIES AND IMMUNOCONJUGATES AND METHODS FOR USING THEM | 2009 |
|
RU2553566C2 |
| ANTI-CD79b ANTIBODIES AND IMMUNOCONJUGATES AND METHODS FOR USING THEM | 2008 |
|
RU2511410C2 |
| ANTIBODY-DRUG CONJUGATES AND METHODS OF USING SAID CONJUGATES OF PYRROLOBENZODIAZEPINE | 2016 |
|
RU2736725C1 |
| OPTIMIZED OPTIONS OF ANTI-VEGF ANTIBODIES | 2016 |
|
RU2763916C2 |
| ANTI-FcRH5 ANTIBODIES | 2014 |
|
RU2687132C2 |
| ANTI-TAT226 ANTIBODIES AND IMMUNOCONJUGATES | 2007 |
|
RU2448980C2 |
| ANTIBODIES AGAINST CD79b, DRUG CONJUGATES AND THEIR USE | 2019 |
|
RU2805251C2 |
| METHODS OF TREATING CANCER USING ANTAGONISTS BINDING TO COMPONENTS OF THE SIGNAL PATH PD-1, AND TAXANES | 2014 |
|
RU2719487C2 |
| PHARMACEUTICAL COMPOSITIONS OF HER2 ANTIBODY CONJUGATE | 2020 |
|
RU2795196C2 |
